Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Formoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL30154976 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL30969874 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL15856256 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL4247 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL458736 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL117865 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3679114 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL6547706 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL6528975 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL29640690 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| CN-112393968-B | Method for expanding dynamic modulus frequency domain data of viscoelastic material | 湖南工业大学 | 2023-05-02 | — | — | CN | claimed |
| CN-115656376-A | Method for separating and detecting formoterol related substances | 苏州易合医药有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115421066-A | Line protection method and device for coping with high-resistance grounding fault of power system | 国网湖北省电力有限公司电力科学研究院 | 2022-12-02 | — | — | CN | claimed |
| CN-112459871-B | Method for calculating reaction rate and method for controlling urea introduction amount of engine | 潍柴动力股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| CN-113211442-B | Singularity processing method of 6-degree-of-freedom robot or 7-degree-of-freedom robot | 山东科技大学 | 2022-06-17 | — | — | CN | claimed |
| CN-114612944-A | Fingerprint identification method based on distortion correction | 杭州远方光电信息股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-113420647-B | Method for creating new style font by expanding and deforming Chinese character center of gravity outwards | 南开大学 | 2022-05-20 | — | — | CN | claimed |
| CN-114062978-A | MEMS magnetic field sensor based on piezoelectric tunnel effect and magnetic field measuring method | 东南大学 | 2022-02-18 | — | — | CN | claimed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | claimed |
| US-20060205806-A1 | Synergistic combination | ALTANA PHARMA AG | 2006-09-14 | — | — | US | claimed |
| US-20060079539-A1 | Synergistic combination | ALTANA PHARMA AG | 2006-04-13 | — | — | US | claimed |
| US-6624181-B1 | Synergistic combination | ALTANA PHARMA AG (DE) | 2003-09-23 | — | — | US | claimed |
| US-5684199-A | Process for the preparation of an optically pure enantiomer of formoterol | NOVARTIS CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| EP-0737182-A1 | PROCESS FOR THE PREPARATION OF AN OPTICALLY PURE ENANTIOMER OF FORMOTEROL | Novartis AG (CH) | 1996-10-16 | — | — | EP | claimed |
| WO-1995018094-A1 | PROCESS FOR THE PREPARATION OF AN OPTICALLY PURE ENANTIOMER OF FORMOTEROL | CIBA-GEIGY AG (CH) | 1995-07-06 | — | — | WO | claimed |
| US-4904662-A | Raising of pigs | ELI LILLY AND COMPANY (US) | 1990-02-27 | — | — | US | claimed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885ADRB3 287/4885 |
| US-20060205806-A1 | Synergistic combination | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885ADRB3 287/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885ADRB3 287/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885ADRB3 287/4885 |
| US-20060079539-A1 | Synergistic combination | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.